The Iranian Journal of Obstetrics, Gynecology and Infertility

The Iranian Journal of Obstetrics, Gynecology and Infertility

The Role of Estrogen Receptor 1 (ESR1) in Molar Pregnancy: A Narrative Review on Differentiation of Trophoblastic and Disease Progression

Document Type : Review Article

Authors
1 Resident, Department of Obstetrics and Gynecology, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.
2 Professor, Department of Medical Genetics, Medical Genetics Research Center, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.
3 PhD in Molecular Medicine, Department of Obstetrics and Gynecology, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.
4 Associate Professor, Department of Obstetrics and Gynecology, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.
10.22038/ijogi.2026.92681.6597
Abstract
Molar pregnancy is the most common benign form of gestational trophoblastic disease (GTD), but a subset progresses to gestational trophoblastic neoplasia (GTN). ESR1/ERα contributes to normal placental development through syncytiotrophoblast differentiation, extravillous trophoblast invasion, and angiogenic signaling. Although there are reports regarding loss or reduction of ERα expression in molar lesions, direct evidence for ESR1 methylation in molar tissues remains limited. This review was conducted with aim to critically synthesize evidence on ESR1 expression, GTD epigenetics, and possible implications for trophoblast differentiation, invasion, and progression. This study is a narrative review based on the available literature. Direct studies of ESR1 in molar pregnancy are few, older, and mainly immunohistochemistry-based with limited sample sizes. Nevertheless, most report weak, reduced, or absent ERα staining in hydatidiform mole and choriocarcinoma. More recent GTD literature supports the role of genetic and epigenetic abnormalities, specially imprinting defects, NLRP7/KHDC3L, and alterations in trophoblast pathways, but does not directly establish ESR1 promoter methylation in molar tissue. Thus, a link between ESR1 downregulation and epigenetic silencing in molar pregnancy is a testable biological hypothesis rather than a definitive result. ESR1 is currently better regarded as a research target and hypothesis-generating marker than as an established diagnostic or therapeutic biomarker. Future studies should be conducted with multicenter design and proper control that jointly assess ESR1 mRNA, ERα protein, ESR1 promoter methylation, and their relationship with β-hCG level, mole subtype, GTN risk, and treatment response.
Keywords
Subjects

1.     WHO Classification of Tumours Editorial Board. Female Genital Tumours. 5nd ed. Lyon: International Agency for Research on Cancer; 2020.
2.     Ngan HY, Seckl MJ, Berkowitz RS, Xiang Y, Golfier F, Sekharan PK, et al. Diagnosis and management of gestational trophoblastic disease: 2025 update. International Journal of Gynecology & Obstetrics 2025; 171:78-86.
3.     Braga A, Paiva G, Barcellos M, Elias KM, Horowitz NS, Berkowitz RS. Diagnosis and management of molar pregnancies. Hematology/Oncology Clinics of North America 2024; 38(6):1149-59.
4.     Lok C, Van Trommel N, Braicu EI, Planchamp F, Berkowitz R, Seckl M, et al. Practical guidelines for the treatment of gestational trophoblastic disease: collaboration of the European organisation for the treatment of trophoblastic disease (EOTTD)–European society of gynaecologic oncology (ESGO)–Gynecologic cancer intergroup (GCIG)–International society for the study of trophoblastic diseases (ISSTD). Journal of Clinical Oncology 2025; 43(18):2119-28.
5.     Bahutair SN, Dube R, Kuruba MG, Salama RA, Patni MA, Kar SS, et al. Molecular basis of hydatidiform moles—a systematic review. International Journal of Molecular Sciences 2024; 25(16):8739.
6.     Sanchez-Delgado M, Martin-Trujillo A, Tayama C, Vidal E, Esteller M, Iglesias-Platas I, et al. Absence of maternal methylation in biparental hydatidiform moles from women with NLRP7 maternal-effect mutations reveals widespread placenta-specific imprinting. PLoS genetics 2015; 11(11):e1005644.
7.     Demond H, Anvar Z, Jahromi BN, Sparago A, Verma A, Davari M, et al. A KHDC3L mutation resulting in recurrent hydatidiform mole causes genome-wide DNA methylation loss in oocytes and persistent imprinting defects post-fertilisation. Genome medicine 2019; 11(1):84.
8.     Liu L, Tang L, Chen S, Zheng L, Ma X. Decoding the molecular pathways governing trophoblast migration and placental development; a literature review. Frontiers in endocrinology 2024; 15:1486608.
9.     Rusidzé M, Gargaros A, Fébrissy C, Dubucs C, Weyl A, Ousselin J, et al. Estrogen actions in placental vascular morphogenesis and spiral artery remodeling: a comparative view between humans and mice. Cells 2023; 12(4):620.
10.  Rusidze M, Faure MC, Sicard P, Raymond-Letron I, Giton F, Vessieres E, et al. Loss of function of the maternal membrane oestrogen receptor ERα alters expansion of trophoblast cells and impacts mouse fertility. Development 2022; 149(19):dev200683.
11.  Kumar P, Kamat A, Mendelson CR. Estrogen receptor α (ERα) mediates stimulatory effects of estrogen on aromatase (CYP19) gene expression in human placenta. Molecular Endocrinology 2009; 23(6):784-93.
12.  Gambino YP, Maymó JL, Pérez-Pérez A, Dueñas JL, Sánchez-Margalet V, Calvo JC, et al. 17Beta-estradiol enhances leptin expression in human placental cells through genomic and nongenomic actions. Biology of reproduction 2010; 83(1):42-51.
13.  Wang H, Han X, Wu Z, Guo M, Luo S, Fang L, et al. G protein-coupled estrogen receptor promotes human extravillous trophoblast invasion via YAP-Snail-mediated CYR61 expression. Cellular Signalling 2025:112033.
14.  Cheng JC, Fang L, Li Y, Thakur A, Hoodless PA, Guo Y, et al. G protein-coupled estrogen receptor stimulates human trophoblast cell invasion via YAP-mediated ANGPTL4 expression. Communications biology 2021; 4(1):1285.
15.  Maekawa R, Mihara Y, Sato S, Okada M, Tamura I, Shinagawa M, et al. Aberrant DNA methylation suppresses expression of estrogen receptor 1 (ESR1) in ovarian endometrioma. Journal of ovarian research 2019; 12(1):14.
16.  Dasgupta C, Chen M, Zhang H, Yang S, Zhang L. Chronic hypoxia during gestation causes epigenetic repression of the estrogen receptor-α gene in ovine uterine arteries via heightened promoter methylation. Hypertension 2012; 60(3):697-704.
17.  Quintas-Granados LI, Cortés H, Carmen MG, Leyva-Gómez G, Bustamante-Montes LP, Rodríguez-Morales M, et al. The high methylation level of a novel 151-bp CpG island in the ESR1 gene promoter is associated with a poor breast cancer prognosis. Cancer Cell International 2021; 21(1):649.
18.  Bhandari RK, Taylor JA, Sommerfeld-Sager J, Tillitt DE, Ricke WA, Vom Saal FS. Estrogen receptor 1 expression and methylation of Esr1 promoter in mouse fetal prostate mesenchymal cells induced by gestational exposure to bisphenol A or ethinylestradiol. Environmental epigenetics 2019; 5(3):dvz012.
19.  El-Shalakany AH, Kamel KM, Ismail AM, Salah L, Fahmy SE, Ammar EE. Estrogen and progesterone receptors and telomerase enzyme immunohistochemical detection in gestational trophoblastic tumors. International Journal of Gynecological Cancer 2006; 16(5):1918-26.
20.  Cheung AN, Ngan HY, Ng WF, Khoo US. The expression of cathepsin D, oestrogen receptor and progestogen receptor in hydatidiform mole—an immunohistochemical study. Histopathology 1995; 27(4):341-7.
21.  Shoni M, Nagymanyoki Z, Vitonis AF, Jimenez C, Ng SW, Quade BJ, et al. p-21-Activated kinase-1,-4 and-6 and estrogen receptor expression pattern in normal placenta and gestational trophoblastic diseases. Gynecologic Oncology 2013; 131(3):759-63.
22.  Braga A, Coutinho L, Chagas M, Soares JP, Callado GY, Alevato R, et al. Molar pregnancy: early diagnosis, clinical management, and the role of referral centers. Diagnostics 2025; 15(15):1953.